Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies

American Journal of Pathology

Volumn 176, Issue 4, 2010, Pages 1863-1877

  Gazzerro, Elisabetta ^a   Assereto, Stefania ^a   Bonetto, Andrea ^a   Sotgia, Federica ^a,b   Scarfi, Sonia ^a   Pistorio, Angela ^c   Bonuccelli, Gloria ^b   Cilli, Michele ^d   Bruno, Claudio ^a   Zara, Federico ^a   Lisanti, Michael P ^a,b   Minetti, Carlo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SARCOGLYCAN; BETA DYSTROGLYCAN; BORTEZOMIB; DYSTROPHIN; PROTEASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BECKER MUSCULAR DYSTROPHY; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MUSCLE BIOPSY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

EID: 77950583657     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090468     Document Type: Article

References (44)

1. Nowak KJ, Davies KE: Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 2004, 5:872-876
2. Deconinck N, Dan B: Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007, 36:1-7 (Pubitemid 46427791)
3. Kumamoto T, Fujimoto S, Ito T, Horinouchi H, Ueyama H, Tsuda T: Proteasome expression in the skeletal muscles of patients with muscular dystrophy. Acta Neuropathol 2000, 100:595-602
4. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP: Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 2003, 163:1663-1675 (Pubitemid 37175113)
5. Assereto S, Stringara S, Sotgia F, Bonuccelli G, Broccolini A, Pedemonte M, Traverso M, Biancheri R, Zara F, Bruno C, Lisanti MP, Minetti C: Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment. Am J Physiol Cell Physiol 2006, 290:C577-C582
6. Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758
7. Armand JP, Burnett AK, Drach J, Harousseau JL, Lowenberg B, San Miguel J: The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. Oncologist 2007, 12:281-290 (Pubitemid 46556794)
8. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P: Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007, 21:30-36 (Pubitemid 44921831)
9. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL, Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC: Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007, 117:889-901 (Pubitemid 46556745)
10. Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, Lisanti MP: Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 2007, 6:1242-1248 (Pubitemid 47327991)
11. Vainzof M, Ayub-Guerrieri D, Onofre PC, Martins PC, Lopes VF, Zilberztajn D, Maia LS, Sell K, Yamamoto LU: Animal models for genetic neuromuscular diseases. J Mol Neurosci 2008, 34:241-248
12. Costelli P, Bossola M, Muscaritoli M, Grieco G, Bonelli G, Bellantone R, Doglietto GB, Baccino FM, Rossi Fanelli F: Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine 2002, 19:1-5
13. Rasband WS. ImageJ, US National Institute of Health, Bethesda MD, 1997-2007
14. Dubowitz V, Sewry C: Muscle biopsy. Edited by Saunders, M.J.H. and L.C. Elsevier, Philadelphia, 2007, p. 84
15. Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G: Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 2006, 168:918-926 (Pubitemid 43327744)
16. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M: Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006, 98:1142-1157 (Pubitemid 44288789)
17. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004, 22:4804-4809 (Pubitemid 41185092)
18. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA: Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:37-45 (Pubitemid 350234263)
19. Wakayama Y, Inoue M, Kojima H, Jimi T, Yamashita S, Kumagai T, Shibuya S, Hara H, Oniki H: Altered alpha1-syntrophin expression in myofibers with Duchenne and Fukuyama muscular dystrophies. Histol Histopathol 2006, 21:23-34 (Pubitemid 43033713)
20. Repetto S, Bado M, Broda P, Lucania G, Masetti E, Sotgia F, Carbone I, Pavan A, Bonilla E, Cordone G, Lisanti MP, Minetti C: Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy. Biochem Biophys Res Commun 1999, 261:547-550 (Pubitemid 29408095)
21. Vaghy PL, Fang J, Wu W, Vaghy LP: Increased caveolin-3 levels in mdx mouse muscles. FEBS Lett 1998, 431:125-127 (Pubitemid 28330866)
22. Sotgia F, Lee JK, Das K, Bedford M, Petrucci TC, Macioce P, Sargiacomo M, Bricarelli FD, Minetti C, Sudol M, Lisanti MP: Caveolin-3 directly interacts with the C-terminal tail of beta-dystroglycan. Identification of a central WW-like domain within caveolin family members. J Biol Chem 2000, 275:38048-38058 (Pubitemid 32004928)
23. Li H, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A: Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet 2009, 18:2584-2598
24. Straface G, Aprahamian T, Flex A, Gaetani E, Biscetti F, Smith RC, Pecorini G, Pola E, Angelini F, Stigliano E, Castellot JJ Jr, Losordo DW, Pola R: Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration. J Cell Mol Med 2008, 13:2424-2435
25. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG: Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009, 18:482-496
26. Glesby MJ, Rosenmann E, Nylen EG, Wrogemann K: Serum CK, calcium, magnesium, and oxidative phosphorylation in mdx mouse muscular dystrophy. Muscle Nerve 1988, 11:852-856
27. Traverso M, Malnati M, Minetti C, Regis S, Tedeschi S, Pedemonte M, Bruno C, Biassoni R, Zara F: Multiplex real-time PCR for detection of deletions and duplications in dystrophin gene. Biochem Biophys Res Commun 2006, 339:145-150 (Pubitemid 41697527)
28. Ludolph AC: Neuromuscular diseases: new hopes for alleviation and elimination. Lancet Neurol 2009, 8:16-17
29. Costelli P, Reffo P, Penna F, Autelli R, Bonelli G, Baccino FM: Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005, 37:2134-2146
30. Briguet A, Erb M, Courdier-Fruh I, Barzaghi P, Santos G, Herzner H, Lescop C, Siendt H, Henneboehle M, Weyermann P, Magyar JP, Dubach-Powell J, Metz G, Meier T: Effect of calpain and proteasome inhibition on Ca2+-dependent proteolysis and muscle histopathology in the mdx mouse. FASEB J 2008, 22:4190-4200
31. Whitehead NP, Yeung EW, Allen DG: Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006, 33:657-662
32. Galbiati F, Volonte D, Minetti C, Chu JB, Lisanti MP: Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex. J Biol Chem 1999, 274:25632-25641 (Pubitemid 129530737)
33. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM: Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004, 22:115-119 (Pubitemid 41095122)
34. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ: Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006, 107:916-924 (Pubitemid 44291139)
35. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM: A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 2007, 13:1516-1522 (Pubitemid 46450443)
36. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S: The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009, 84:6-14
37. Magnani M, Crinelli R, Bianchi M, Antonelli A: The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr Drug Targets 2000, 1:387-399
38. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, Van Der Meulen JH, Cha HJ, Pistilli EE, Partridge TA, Hoffman EP, Nagaraju K: Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009, 39:591-602
39. Muntoni F, Torelli S, Ferlini A: Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003, 2:731-740 (Pubitemid 37443515)
40. Cox GA, Sunada Y, Campbell KP, Chamberlain JS: Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet 1994, 8:333-339 (Pubitemid 24375597)
41. Gardner KL, Kearney JA, Edwards JD, Rafael-Fortney JA: Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy. Gene Ther 2006, 13:744-751
42. Li D, Yue Y, Duan D: Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am J Pathol 2008, 172:1332-1341 (Pubitemid 351671546)
43. Judge LM, Haraguchiln M, Chamberlain JS: Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J Cell Sci 2006, 119:1537-1546 (Pubitemid 43732980)
44. Li D, Long C, Yue Y, Duan D: Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice. Hum Mol Genet 2009, 18:1209-1220